Depression

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Complications of Depression...
• Diagnosis
• Treatment
• Antidepressants and Drug Tr...
• Psychotherapy
• Other Treatments
• Lifestyle Changes
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approval In 2007, the Food and Drug Administration (FDA) approved the atypical antipsychotic drug aripiprazole (Abilify) for treatment of major depression in adults. Aripiprazole is used for treatment of schizophrenia and bipolar disorder. For depression, it is used in combination with antidepressant drug therapy. - 5 Comments

Asthma in adults

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Symptoms
• Causes
• Prognosis
• Risk Factors
• Diagnosis
• Treatment
• Quick-Relief Medications...
• Long-Term Relief Medication...
• Other Treatments
• Managing Asthma
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Warning In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks. - 0 Comments

Asthma in children and adolescents

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Prognosis
• Risk Factors
• Symptoms
• Diagnosis
• Treatment
• Quick-Relief Medications...
• Long-Term Relief Medication...
• Other Treatments
• Managing Asthma
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Warning In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment. - 0 Comments

Insomnia

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes of Short-Term or Tra...
• Causes of Chronic Insomnia...
• Risk Factors
• Prognosis
• Diagnosis
• Treatment
• Medications
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Sedative Hypnotic Drug Warnings In March 2007, the FDA ordered stronger warning labels on sedative hypnotic drugs. These medications include benzodiazepine and non-benzodiazepine drugs, such as zolpidem (Ambien), eszopiclone (Lunesta), ramelteon (Rozerem), and triazolam (Halcion). The FDA warned that these drugs may be associated with:

• Severe allergic reactions (anaphylaxis) and severe facial swelling (angioedema), which can occur even the first time a drug is taken
• Complex sleep-related behaviors, such as sleep driving, making phone calls, and preparing and eating food while asleep

Patients who take sleeping pills should be sure to follow the directions. - 5 Comments

Exercise

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Recommended Exercise Method...
• Exercise's Effects on the H...
• Exercise's Effects on Diabe...
• Exercise's Effects on Bones...
• Exercise's Effects on the L...
• Exercise's Effects on Weigh...
• Exercise's Effects on Other...
• Complications
• Motivation
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Chronic Conditions and Exercise:

• A new study found that aerobic and resistance training significantly reduced fatigue in men undergoing radiation treatments for prostate cancer. Fatigue is a common side effect of such treatments.
• Doctors at the Mayo Clinic found that exercise improves the physical and emotional well-being of patients with Alzheimer's disease. The patients exercised for as little as 60 minutes each week. - 1 Comment
  Read More ›

Depression

Oct 08, 2008 - Overview

• Signs and Symptoms
• Causes
• Risk Factors
• Diagnosis
• Preventive Care
• Treatment Approach
• Other Considerations
• Supporting Research

HEALTH GUIDE REFERENCE FROM A.D.A.M Depression is a mood disorder in which feelings of loss, anger, sadness, or frustration interfere with everyday life. Depression affects about 17 million Americans each year. It can be mild, moderate, or severe and occur as a single episode, recurring episodes, or chronic depression (lasting more than 2 years). - 0 Comments

Urinary incontinence

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Risk Factors
• Diagnosis
• Prognosis
• Treatment
• Lifestyle Changes
• Other Treatments
• Behavioral Treatments
• Medications
• Surgery
• Other Procedures
• Catheters and Collection De...
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Sling Procedure Versus Burch Colposuspension The sling procedure is better than Burch colposuspension in treating stress incontinence but may cause more post-operative urinary complications, according to results from an important 2007 New England Journal of Medicine study. In the first large-scale clinical trial to directly compare these two types of surgery, 47% of women who underwent the sling procedure had no urinary incontinence 2 years after surgery, compared with 38% of women who received the Burch procedure. However, 63% of women who had the sling procedure (and 47% of women who underwent the Burch procedure) experienced urinary tract infections following surgery. - 0 Comments

Restless legs syndrome and related disorders

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Complications
• Diagnosis
• Treatment
• Medications
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Treatment

• The American Academy of Sleep Medicine recommends medications for restless legs syndrome (RLS) or periodic limb movement disorder (PLMD) only for persons who fulfill strict diagnostic criteria and experience too much daytime sleepiness as a result of these conditions. (Excessive daytime sleepiness results from nighttime sleeplessness due to RLS or PLMD symptoms).
• The U.S. Food and Drug Administration (FDA) announced in March 2007 that the dopamine agonist drug pergolide (Permax) has been voluntarily withdrawn from the market. - 2 Comments
  Read More ›

Colds and the flu

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Diagnosis
• Complications
• Risk Factors
• Prevention
• Treatment
• Medications
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Vaccine News:

• On September 28, 2007, the U.S. Food and Drug Administration (FDA) approved a new brand of inactivated influenza ("flu") vaccine, Alfuria, for adults aged 18 years or older. This vaccine is given by injection.
• On September 19, 2007, the FDA approved the use of the live flu vaccine (FluMist) in healthy children as young as 2 years of age. - 0 Comments
  Read More ›